Semax

Semax was synthesized by the Institute of Molecular Genetics of the Russian Academy of Sciences in 1982. It was developed to create a stable, non-hormonal derivative of adrenocorticotropic hormone (ACTH) for cognitive enhancement. What it is: Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH 4-10 fragment. It is a nootropic and neuroprotective peptide administered primarily via nasal spray. Proposed Mechanisms & Research Findings: It acts as a melanocortin receptor agonist and stimulates the release of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF). It modulates neurotransmitter systems (dopamine and serotonin) and provides robust neuroprotective effects during hypoxia. Regulatory & Safety Status: It is not FDA approved. In Russia, it is approved for clinical use and is included on the Vital and Essential Drugs list for stroke recovery and cognitive repair. Gray-market sourcing lacks quality control. Athletic & Anti-Doping Status: Semax is not prohibited by WADA or USADA, but athletes should use caution as it affects central nervous system activity.